For research use only. Not for therapeutic Use.
Burosumab（Cat No.:I042207）is a monoclonal antibody that targets and inhibits fibroblast growth factor 23 (FGF23), a protein involved in phosphate regulation and bone metabolism. Elevated levels of FGF23 can lead to phosphate wasting and disorders like X-linked hypophosphatemia (XLH), a rare genetic condition that causes rickets and osteomalacia. By blocking FGF23, burosumab aims to restore normal phosphate levels, improving bone mineralization and growth. It is FDA-approved for treating XLH and is being studied for its potential in other phosphate metabolism-related conditions, offering significant benefits for patients with phosphate deficiencies.
| Catalog Number | I042207 |
| CAS Number | 1610833-03-8 |
| Purity | ≥95% |
